Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Equity Average (2017 - 2025)

Historic Equity Average for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $414.8 million.

  • Adma Biologics' Equity Average rose 9742.79% to $414.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $414.8 million, marking a year-over-year increase of 9742.79%. This contributed to the annual value of $242.1 million for FY2024, which is 6861.34% up from last year.
  • Adma Biologics' Equity Average amounted to $414.8 million in Q3 2025, which was up 9742.79% from $385.9 million recorded in Q2 2025.
  • Adma Biologics' Equity Average's 5-year high stood at $414.8 million during Q3 2025, with a 5-year trough of $100.4 million in Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $144.5 million (2024), whereas its average is $184.0 million.
  • In the last 5 years, Adma Biologics' Equity Average crashed by 292.88% in 2024 and then soared by 15005.43% in 2025.
  • Adma Biologics' Equity Average (Quarter) stood at $122.0 million in 2021, then increased by 3.45% to $126.2 million in 2022, then rose by 13.59% to $143.3 million in 2023, then soared by 102.66% to $290.5 million in 2024, then surged by 42.8% to $414.8 million in 2025.
  • Its Equity Average stands at $414.8 million for Q3 2025, versus $385.9 million for Q2 2025 and $361.2 million for Q1 2025.